Diabetes Mellitus, Type 2 Clinical Trial
Official title:
A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
Status | Completed |
Enrollment | 2705 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: 1. Patients completing the entire treatment period of the preceding double-blind trial 1245.19, 1245.20 or 1245.23 with or without rescue therapy. 2. Signed and dated written informed consent by date of Visit 1 in accordance with Good Clinical Practice and local legislation. Exclusion criteria: 1. Patient who meet one or more of the withdrawal criteria of the treatment period of the previous trial 1245.19, 1245.20 or 1245.23. 2. Indication of liver disease, defined by serum levels of either alanine aminotransferase , aspartate aminotransferase, or alkaline phosphatase above 3 x upper limit of normal as determined during last visit of preceding trial. 3. Impaired renal function defined as glomerular filtration rate<30 ml/min (severe renal impairment, Modification of Diet in Renal Disease formula) as determined during last visit of preceding trial. 4. Contraindications to sitagliptin, pioglitazone, metformin or sulfonylurea according to local label, which started during trial participation in 1245.19, 1245.20 or 1245.23 5. Pre-menopausal women (last menstruation < or = 1 year prior to informed consent) who are nursing or pregnant or are of child-bearing potential and are not practicing an acceptable method of birth control, or do not plan to continue using this method throughout the study and do not agree to submit to periodic pregnancy testing during participation in the trial. Acceptable methods of birth control include tubal ligation, transdermal patch, intra uterine devices/systems, oral, implantable or injectable contraceptives, sexual abstinence (if acceptable by local authorities), double barrier method and vasectomised partner. 6. Alcohol or drug abuse within the 3 months prior to informed consent that would interfere with trial participation or any ongoing condition leading to a decreased compliance to study procedures or study drug intake. 7. Participation in another trial with an investigational drug within 30 days prior to informed consent (except 1245.19, 1245.20 and 1245.23). 8. Any other clinical condition that would jeopardize patient's safety while participating in this clinical trial. |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | 1245.31.32008 Boehringer Ingelheim Investigational Site | Bruxelles | |
Belgium | 1245.31.32023 Boehringer Ingelheim Investigational Site | Bruxelles | |
Belgium | 1245.31.32003 Boehringer Ingelheim Investigational Site | De Pinte | |
Belgium | 1245.31.32015 Boehringer Ingelheim Investigational Site | Deurne | |
Belgium | 1245.31.32016 Boehringer Ingelheim Investigational Site | Deurne | |
Belgium | 1245.31.32025 Boehringer Ingelheim Investigational Site | Gozée | |
Belgium | 1245.31.32019 Boehringer Ingelheim Investigational Site | Leopoldsburg | |
Belgium | 1245.31.32024 Boehringer Ingelheim Investigational Site | Linkebeek | |
Belgium | 1245.31.32021 Boehringer Ingelheim Investigational Site | Mouscron | |
Belgium | 1245.31.32020 Boehringer Ingelheim Investigational Site | Sint-Gillis-Waas | |
Belgium | 1245.31.32018 Boehringer Ingelheim Investigational Site | Tielt | |
Belgium | 1245.31.32026 Boehringer Ingelheim Investigational Site | Tremelo | |
Canada | 1245.31.20022 Boehringer Ingelheim Investigational Site | Brampton | Ontario |
Canada | 1245.31.20057 Boehringer Ingelheim Investigational Site | Brampton | Ontario |
Canada | 1245.31.20032 Boehringer Ingelheim Investigational Site | Calgary | Alberta |
Canada | 1245.31.20011 Boehringer Ingelheim Investigational Site | Chilliwack | British Columbia |
Canada | 1245.31.20035 Boehringer Ingelheim Investigational Site | Corunna | Ontario |
Canada | 1245.31.20023 Boehringer Ingelheim Investigational Site | Edmonton | Alberta |
Canada | 1245.31.20030 Boehringer Ingelheim Investigational Site | Etobicoke | Ontario |
Canada | 1245.31.20026 Boehringer Ingelheim Investigational Site | Halifax | Nova Scotia |
Canada | 1245.31.20019 Boehringer Ingelheim Investigational Site | Hamilton | Ontario |
Canada | 1245.31.20027 Boehringer Ingelheim Investigational Site | Laval | Quebec |
Canada | 1245.31.20017 Boehringer Ingelheim Investigational Site | London | Ontario |
Canada | 1245.31.20029 Boehringer Ingelheim Investigational Site | London | Ontario |
Canada | 1245.31.20060 Boehringer Ingelheim Investigational Site | London | Ontario |
Canada | 1245.31.20003 Boehringer Ingelheim Investigational Site | Markham | Ontario |
Canada | 1245.31.20012 Boehringer Ingelheim Investigational Site | Moncton | New Brunswick |
Canada | 1245.31.20007 Boehringer Ingelheim Investigational Site | Montague | Prince Edward Island |
Canada | 1245.31.20025 Boehringer Ingelheim Investigational Site | Montreal | Quebec |
Canada | 1245.31.20016 Boehringer Ingelheim Investigational Site | Mount Pearl | Newfoundland and Labrador |
Canada | 1245.31.20009 Boehringer Ingelheim Investigational Site | Newmarket | Ontario |
Canada | 1245.31.20040 Boehringer Ingelheim Investigational Site | Oakville | Ontario |
Canada | 1245.31.20024 Boehringer Ingelheim Investigational Site | Paradise | Newfoundland and Labrador |
Canada | 1245.31.20034 Boehringer Ingelheim Investigational Site | Sarnia | Ontario |
Canada | 1245.31.20041 Boehringer Ingelheim Investigational Site | Saskatoon | Saskatchewan |
Canada | 1245.31.20036 Boehringer Ingelheim Investigational Site | Sherbrooke | Quebec |
Canada | 1245.31.20058 Boehringer Ingelheim Investigational Site | St-Romuald | Quebec |
Canada | 1245.31.20008 Boehringer Ingelheim Investigational Site | St. John's | Newfoundland and Labrador |
Canada | 1245.31.20005 Boehringer Ingelheim Investigational Site | Strathroy | Ontario |
Canada | 1245.31.20002 Boehringer Ingelheim Investigational Site | Toronto | Ontario |
Canada | 1245.31.20006 Boehringer Ingelheim Investigational Site | Toronto | Ontario |
Canada | 1245.31.20021 Boehringer Ingelheim Investigational Site | Trois Rivieres | Quebec |
Canada | 1245.31.20028 Boehringer Ingelheim Investigational Site | Vancouver | British Columbia |
Canada | 1245.31.20018 Boehringer Ingelheim Investigational Site | Victoria | British Columbia |
Canada | 1245.31.20033 Boehringer Ingelheim Investigational Site | Victoria | British Columbia |
Canada | 1245.31.20038 Boehringer Ingelheim Investigational Site | Ville Saint-Laurent | Quebec |
Canada | 1245.31.20015 Boehringer Ingelheim Investigational Site | Winnipeg | Manitoba |
China | 1245.31.86007 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86008 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86031 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86032 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86033 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86034 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86035 Boehringer Ingelheim Investigational Site | Beijing | |
China | 1245.31.86058 Boehringer Ingelheim Investigational Site | Chongqing | |
China | 1245.31.86038 Boehringer Ingelheim Investigational Site | Dalian | |
China | 1245.31.86001 Boehringer Ingelheim Investigational Site | Guangzhou | |
China | 1245.31.86003 Boehringer Ingelheim Investigational Site | Guangzhou | |
China | 1245.31.86052 Boehringer Ingelheim Investigational Site | Guangzhou | |
China | 1245.31.86012 Boehringer Ingelheim Investigational Site | Guiyang | |
China | 1245.31.86037 Boehringer Ingelheim Investigational Site | Haerbin | |
China | 1245.31.86020 Boehringer Ingelheim Investigational Site | Hangzhou | |
China | 1245.31.86049 Boehringer Ingelheim Investigational Site | Jinan | |
China | 1245.31.86053 Boehringer Ingelheim Investigational Site | Jinan | |
China | 1245.31.86018 Boehringer Ingelheim Investigational Site | Jingzhou | |
China | 1245.31.86055 Boehringer Ingelheim Investigational Site | Nan Ning | |
China | 1245.31.86056 Boehringer Ingelheim Investigational Site | Nan Ning | |
China | 1245.31.86019 Boehringer Ingelheim Investigational Site | Nanchang | |
China | 1245.31.86042 Boehringer Ingelheim Investigational Site | Nanjing | |
China | 1245.31.86043 Boehringer Ingelheim Investigational Site | Nanjing | |
China | 1245.31.86016 Boehringer Ingelheim Investigational Site | QingDao | |
China | 1245.31.86039 Boehringer Ingelheim Investigational Site | Shanghai | |
China | 1245.31.86054 Boehringer Ingelheim Investigational Site | Shantou | |
China | 1245.31.86057 Boehringer Ingelheim Investigational Site | Shenyang | |
China | 1245.31.86045 Boehringer Ingelheim Investigational Site | Shijiazhuang | |
China | 1245.31.86017 Boehringer Ingelheim Investigational Site | Shiyan | |
China | 1245.31.86013 Boehringer Ingelheim Investigational Site | Suzhou | |
China | 1245.31.86015 Boehringer Ingelheim Investigational Site | Taiyuan | |
China | 1245.31.86036 Boehringer Ingelheim Investigational Site | Tianjin | |
China | 1245.31.86011 Boehringer Ingelheim Investigational Site | Xi'An | |
China | 1245.31.86041 Boehringer Ingelheim Investigational Site | Xi'An | |
China | 1245.31.86014 Boehringer Ingelheim Investigational Site | Xiamen | |
France | 1245.31.33008 Boehringer Ingelheim Investigational Site | Bersée | |
France | 1245.31.33020 Boehringer Ingelheim Investigational Site | Bischheim | |
France | 1245.31.33002 Boehringer Ingelheim Investigational Site | Bondy Cedex | |
France | 1245.31.33016 Boehringer Ingelheim Investigational Site | Bruay La Buissiere | |
France | 1245.31.33001 Boehringer Ingelheim Investigational Site | Corbeil Essonnes | |
France | 1245.31.33010 Boehringer Ingelheim Investigational Site | Croix | |
France | 1245.31.33009 Boehringer Ingelheim Investigational Site | Hautmont | |
France | 1245.31.33003 Boehringer Ingelheim Investigational Site | La Rochelle Cedex 1 | |
France | 1245.31.33045 Boehringer Ingelheim Investigational Site | Marseille | |
France | 1245.31.33004 Boehringer Ingelheim Investigational Site | Narbonne Cedex | |
France | 1245.31.33012 Boehringer Ingelheim Investigational Site | Schiltigheim | |
France | 1245.31.33013 Boehringer Ingelheim Investigational Site | Strasbourg | |
France | 1245.31.33019 Boehringer Ingelheim Investigational Site | Strasbourg | |
France | 1245.31.33007 Boehringer Ingelheim Investigational Site | Vieux Condé | |
France | 1245.31.33018 Boehringer Ingelheim Investigational Site | Wattrelos | |
Germany | 1245.31.49001 Boehringer Ingelheim Investigational Site | Dormagen | |
Germany | 1245.31.49013 Boehringer Ingelheim Investigational Site | Dresden | |
Germany | 1245.31.49016 Boehringer Ingelheim Investigational Site | Düsseldorf | |
Germany | 1245.31.49009 Boehringer Ingelheim Investigational Site | Flörsheim | |
Germany | 1245.31.49015 Boehringer Ingelheim Investigational Site | Frankfurt | |
Germany | 1245.31.49019 Boehringer Ingelheim Investigational Site | Haag | |
Germany | 1245.31.49004 Boehringer Ingelheim Investigational Site | Hatten | |
Germany | 1245.31.49020 Boehringer Ingelheim Investigational Site | Hohenmölsen | |
Germany | 1245.31.49007 Boehringer Ingelheim Investigational Site | Künzing | |
Germany | 1245.31.49002 Boehringer Ingelheim Investigational Site | Neuwied | |
Germany | 1245.31.49008 Boehringer Ingelheim Investigational Site | Nürnberg | |
Germany | 1245.31.49010 Boehringer Ingelheim Investigational Site | Rednitzhembach | |
Germany | 1245.31.49006 Boehringer Ingelheim Investigational Site | Rehburg-Loccum | |
Germany | 1245.31.49011 Boehringer Ingelheim Investigational Site | Rehlingen-Siersburg | |
Germany | 1245.31.49005 Boehringer Ingelheim Investigational Site | Saarbrücken | |
Germany | 1245.31.49022 Boehringer Ingelheim Investigational Site | Schauenburg | |
Germany | 1245.31.49017 Boehringer Ingelheim Investigational Site | St. Ingbert/Oberwürzbach | |
Germany | 1245.31.49003 Boehringer Ingelheim Investigational Site | Unterschneidheim | |
Greece | 1245.31.30004 Boehringer Ingelheim Investigational Site | Thessaloniki | |
India | 1245.31.91005 Boehringer Ingelheim Investigational Site | Bangalore | |
India | 1245.31.91006 Boehringer Ingelheim Investigational Site | Bangalore | |
India | 1245.31.91008 Boehringer Ingelheim Investigational Site | Bangalore | |
India | 1245.31.91003 Boehringer Ingelheim Investigational Site | Belgaum | |
India | 1245.31.91004 Boehringer Ingelheim Investigational Site | Chennai | |
India | 1245.31.91009 Boehringer Ingelheim Investigational Site | Chennai | |
India | 1245.31.91001 Boehringer Ingelheim Investigational Site | Coimbatore | |
India | 1245.31.91101 Boehringer Ingelheim Investigational Site | Coimbatore | |
India | 1245.31.91015 Boehringer Ingelheim Investigational Site | Gulbarga | |
India | 1245.31.91104 Boehringer Ingelheim Investigational Site | Indore | |
India | 1245.31.91103 Boehringer Ingelheim Investigational Site | Maharashtra | |
India | 1245.31.91002 Boehringer Ingelheim Investigational Site | Mumbai | |
India | 1245.31.91007 Boehringer Ingelheim Investigational Site | Mumbai, Maharastra | |
India | 1245.31.91010 Boehringer Ingelheim Investigational Site | Nagpur | |
India | 1245.31.91012 Boehringer Ingelheim Investigational Site | New Delhi | |
India | 1245.31.91014 Boehringer Ingelheim Investigational Site | Pune | |
India | 1245.31.91105 Boehringer Ingelheim Investigational Site | Pune | |
Ireland | 1245.31.35304 Boehringer Ingelheim Investigational Site | Birr, Co. Offaly | |
Ireland | 1245.31.35302 Boehringer Ingelheim Investigational Site | Co. Cork | |
Ireland | 1245.31.35305 Boehringer Ingelheim Investigational Site | Co. Galway | |
Ireland | 1245.31.35303 Boehringer Ingelheim Investigational Site | Co. Wexford | |
Ireland | 1245.31.35306 Boehringer Ingelheim Investigational Site | Co. Wexford | |
Japan | 1245.31.81007 Boehringer Ingelheim Investigational Site | Chiyoda-ku, Tokyo | |
Japan | 1245.31.81001 Boehringer Ingelheim Investigational Site | Chuo-ku, Tokyo | |
Japan | 1245.31.81002 Boehringer Ingelheim Investigational Site | Chuo-ku, Tokyo | |
Japan | 1245.31.81005 Boehringer Ingelheim Investigational Site | Ebetsu, Hokkaido | |
Japan | 1245.31.81004 Boehringer Ingelheim Investigational Site | Kamakura, Kanagawa | |
Japan | 1245.31.81003 Boehringer Ingelheim Investigational Site | Minato-ku, Tokyo | |
Japan | 1245.31.81006 Boehringer Ingelheim Investigational Site | Shinjuku-ku, Tokyo | |
Japan | 1245.31.81008 Boehringer Ingelheim Investigational Site | Shinjuku-ku, Tokyo | |
Japan | 1245.31.81009 Boehringer Ingelheim Investigational Site | Suita, Osaka | |
Japan | 1245.31.81010 Boehringer Ingelheim Investigational Site | Ube, Yamaguchi | |
Japan | 1245.31.81012 Boehringer Ingelheim Investigational Site | Urasoe, Okinawa | |
Japan | 1245.31.81013 Boehringer Ingelheim Investigational Site | Urasoe, Okinawa | |
Korea, Republic of | 1245.31.82012 Boehringer Ingelheim Investigational Site | Anyang | |
Korea, Republic of | 1245.31.82011 Boehringer Ingelheim Investigational Site | Goyang | |
Korea, Republic of | 1245.31.82009 Boehringer Ingelheim Investigational Site | Ilsan | |
Korea, Republic of | 1245.31.82001 Boehringer Ingelheim Investigational Site | Incheon | |
Korea, Republic of | 1245.31.82006 Boehringer Ingelheim Investigational Site | Jeonju | |
Korea, Republic of | 1245.31.82004 Boehringer Ingelheim Investigational Site | Pusan | |
Korea, Republic of | 1245.31.82005 Boehringer Ingelheim Investigational Site | Seoul | |
Korea, Republic of | 1245.31.82007 Boehringer Ingelheim Investigational Site | Seoul | |
Korea, Republic of | 1245.31.82008 Boehringer Ingelheim Investigational Site | Seoul | |
Korea, Republic of | 1245.31.82010 Boehringer Ingelheim Investigational Site | Seoul | |
Korea, Republic of | 1245.31.82014 Boehringer Ingelheim Investigational Site | Seoul | |
Korea, Republic of | 1245.31.82002 Boehringer Ingelheim Investigational Site | Suwon | |
Korea, Republic of | 1245.31.82003 Boehringer Ingelheim Investigational Site | Wonju | |
Mexico | 1245.31.52003 Boehringer Ingelheim Investigational Site | Guadalajara | |
Mexico | 1245.31.52004 Boehringer Ingelheim Investigational Site | Guadalajara | |
Mexico | 1245.31.52001 Boehringer Ingelheim Investigational Site | Monterrey | |
Mexico | 1245.31.52002 Boehringer Ingelheim Investigational Site | Monterrey | |
Philippines | 1245.31.63002 Boehringer Ingelheim Investigational Site | Cebu | |
Philippines | 1245.31.63003 Boehringer Ingelheim Investigational Site | Davao City | |
Philippines | 1245.31.63001 Boehringer Ingelheim Investigational Site | Manila | |
Philippines | 1245.31.63004 Boehringer Ingelheim Investigational Site | Manila | |
Philippines | 1245.31.63005 Boehringer Ingelheim Investigational Site | Manila | |
Slovakia | 1245.31.74005 Boehringer Ingelheim Investigational Site | Bratislava | |
Slovakia | 1245.31.74002 Boehringer Ingelheim Investigational Site | Lucenec | |
Slovakia | 1245.31.74006 Boehringer Ingelheim Investigational Site | Nitra | |
Slovakia | 1245.31.74014 Boehringer Ingelheim Investigational Site | Nove Zamky | |
Slovakia | 1245.31.74001 Boehringer Ingelheim Investigational Site | Povazska Bystrica | |
Slovakia | 1245.31.74004 Boehringer Ingelheim Investigational Site | Presov | |
Slovakia | 1245.31.74003 Boehringer Ingelheim Investigational Site | Trebisov | |
Slovenia | 1245.31.38003 Boehringer Ingelheim Investigational Site | Celje | |
Slovenia | 1245.31.38002 Boehringer Ingelheim Investigational Site | Koper | |
Slovenia | 1245.31.38001 Boehringer Ingelheim Investigational Site | Maribor | |
Switzerland | 1245.31.41004 Boehringer Ingelheim Investigational Site | Lugano | |
Switzerland | 1245.31.41003 Boehringer Ingelheim Investigational Site | Rorschach | |
Taiwan | 1245.31.88010 Boehringer Ingelheim Investigational Site | Kaohsiung | |
Taiwan | 1245.31.88011 Boehringer Ingelheim Investigational Site | Kaohsiung | |
Taiwan | 1245.31.88012 Boehringer Ingelheim Investigational Site | Kaohsiung | |
Taiwan | 1245.31.88013 Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | |
Taiwan | 1245.31.88009 Boehringer Ingelheim Investigational Site | Taichung | |
Taiwan | 1245.31.88014 Boehringer Ingelheim Investigational Site | Tainan | |
Taiwan | 1245.31.88006 Boehringer Ingelheim Investigational Site | Taipei | |
Taiwan | 1245.31.88021 Boehringer Ingelheim Investigational Site | Taipei | |
Taiwan | 1245.31.88008 Boehringer Ingelheim Investigational Site | Taoyuan County | |
Turkey | 1245.31.90003 Boehringer Ingelheim Investigational Site | Erzurum | |
Turkey | 1245.31.90001 Boehringer Ingelheim Investigational Site | Gaziantep | |
Turkey | 1245.31.90002 Boehringer Ingelheim Investigational Site | Istanbul | |
Turkey | 1245.31.90006 Boehringer Ingelheim Investigational Site | Istanbul | |
Turkey | 1245.31.90004 Boehringer Ingelheim Investigational Site | Izmir | |
Ukraine | 1245.31.75002 Boehringer Ingelheim Investigational Site | Dnepropetrovsk | |
Ukraine | 1245.31.75001 Boehringer Ingelheim Investigational Site | Kharkiv | |
Ukraine | 1245.31.75006 Boehringer Ingelheim Investigational Site | Lviv | |
Ukraine | 1245.31.75004 Boehringer Ingelheim Investigational Site | Vinnitsa | |
Ukraine | 1245.31.75003 Boehringer Ingelheim Investigational Site | Vinnytsya | |
United States | 1245.31.10117 Boehringer Ingelheim Investigational Site | Arkansas City | Kansas |
United States | 1245.31.10071 Boehringer Ingelheim Investigational Site | Asheboro | North Carolina |
United States | 1245.31.10145 Boehringer Ingelheim Investigational Site | Birmingham | Alabama |
United States | 1245.31.10129 Boehringer Ingelheim Investigational Site | Carlisle | Ohio |
United States | 1245.31.10033 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee |
United States | 1245.31.10001 Boehringer Ingelheim Investigational Site | Chicago | Illinois |
United States | 1245.31.10154 Boehringer Ingelheim Investigational Site | Chino | California |
United States | 1245.31.10045 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio |
United States | 1245.31.10119 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio |
United States | 1245.31.10137 Boehringer Ingelheim Investigational Site | Clearwater | Florida |
United States | 1245.31.10003 Boehringer Ingelheim Investigational Site | Dearborn | Michigan |
United States | 1245.31.10080 Boehringer Ingelheim Investigational Site | Decatur | Georgia |
United States | 1245.31.10159 Boehringer Ingelheim Investigational Site | Des Moines | Iowa |
United States | 1245.31.10014 Boehringer Ingelheim Investigational Site | Dubuque | Iowa |
United States | 1245.31.10130 Boehringer Ingelheim Investigational Site | Gallipolis | Ohio |
United States | 1245.31.10162 Boehringer Ingelheim Investigational Site | Glendale | Arizona |
United States | 1245.31.10156 Boehringer Ingelheim Investigational Site | Houston | Texas |
United States | 1245.31.10151 Boehringer Ingelheim Investigational Site | Hurst | Texas |
United States | 1245.31.10133 Boehringer Ingelheim Investigational Site | Jupiter | Florida |
United States | 1245.31.10143 Boehringer Ingelheim Investigational Site | Killeen | Texas |
United States | 1245.31.10146 Boehringer Ingelheim Investigational Site | Louisville | Kentucky |
United States | 1245.31.10112 Boehringer Ingelheim Investigational Site | Memphis | Tennessee |
United States | 1245.31.10124 Boehringer Ingelheim Investigational Site | Mesa | Arizona |
United States | 1245.31.10006 Boehringer Ingelheim Investigational Site | Miami | Florida |
United States | 1245.31.10158 Boehringer Ingelheim Investigational Site | Mount Pleasant | South Carolina |
United States | 1245.31.10059 Boehringer Ingelheim Investigational Site | New Hyde Park | New York |
United States | 1245.31.10157 Boehringer Ingelheim Investigational Site | Newton | Kansas |
United States | 1245.31.10038 Boehringer Ingelheim Investigational Site | Northglenn | Colorado |
United States | 1245.31.10077 Boehringer Ingelheim Investigational Site | Perry | Georgia |
United States | 1245.31.10108 Boehringer Ingelheim Investigational Site | Phoenix | Arizona |
United States | 1245.31.10085 Boehringer Ingelheim Investigational Site | Plantation | Florida |
United States | 1245.31.10149 Boehringer Ingelheim Investigational Site | Rancho Cucamonga | California |
United States | 1245.31.10034 Boehringer Ingelheim Investigational Site | Rochester | New York |
United States | 1245.31.10086 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina |
United States | 1245.31.10155 Boehringer Ingelheim Investigational Site | San Antonio | Texas |
United States | 1245.31.10015 Boehringer Ingelheim Investigational Site | Simpsonville | South Carolina |
United States | 1245.31.10123 Boehringer Ingelheim Investigational Site | Smithtown | New York |
United States | 1245.31.10046 Boehringer Ingelheim Investigational Site | Tempe | Arizona |
United States | 1245.31.10127 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut |
United States | 1245.31.10131 Boehringer Ingelheim Investigational Site | West Hills | California |
Lead Sponsor | Collaborator |
---|---|
Boehringer Ingelheim | Eli Lilly and Company |
United States, Belgium, Canada, China, France, Germany, Greece, India, Ireland, Japan, Korea, Republic of, Mexico, Philippines, Slovakia, Slovenia, Switzerland, Taiwan, Turkey, Ukraine,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes From Baseline in Glycosylated Haemoglobin (HbA1c) (%) After 52 Weeks of Treatment | Change from baseline in HbA1c after 52 weeks | Baseline and 52 weeks | No |
Primary | Changes From Baseline in HbA1c (%) After 76 Weeks of Treatment | Change from baseline in HbA1c after 76 weeks | Baseline and 76 weeks | No |
Secondary | HbA1c (%) Changes From Baseline After 76 Weeks of Treatment | Change from baseline in HbA1c (%) after 76 weeks using MMRM approach | Baseline and 76 weeks | No |
Secondary | Systolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment | Systolic blood pressure - change from baseline after 52 weeks of treatment | Baseline and 52 weeks | No |
Secondary | Systolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment | Systolic blood pressure - change from baseline after 76 weeks of treatment | Baseline and 76 weeks | No |
Secondary | Diastolic Blood Pressure: Change From Baseline After 52 Weeks of Treatment | Diastolic blood pressure - change from baseline after 52 weeks of treatment | Baseline and 52 weeks | No |
Secondary | Diastolic Blood Pressure: Change From Baseline After 76 Weeks of Treatment | Diastolic blood pressure - change from baseline after 76 weeks of treatment | Baseline and 76 weeks | No |
Secondary | Body Weight (kg) Change From Baseline After 52 Weeks of Treatment | Body Weight (kg) - Change From Baseline After 52 Weeks of Treatment | Baseline and 52 weeks | No |
Secondary | Body Weight (kg) Change From Baseline After 76 Weeks of Treatment | Body Weight (kg) - Change From Baseline After 76 Weeks of Treatment | Baseline and 76 weeks | No |
Secondary | Waist Circumference (cm) Change From Baseline After 52 Weeks of Treatment | Waist circumference (cm) - change from baseline after 52 weeks of treatment | Baseline and 52 weeks | No |
Secondary | Waist Circumference (cm) Change From Baseline After 76 Weeks of Treatment | Waist circumference (cm) - change from baseline after 76 weeks of treatment | Baseline and 76 weeks | No |
Secondary | Fasting Plasma Glucose Change From Baseline After 52 Weeks of Treatment | Fasting plasma glucose - change from baseline after 52 weeks of treatment | Baseline and 52 weeks | No |
Secondary | Fasting Plasma Glucose Change From Baseline After 76 Weeks of Treatment | Fasting plasma glucose - change from baseline after 76 weeks of treatment | Baseline and 76 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05666479 -
CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
|
||
Completed |
NCT05647083 -
The Effect of Massage on Diabetic Parameters
|
N/A | |
Active, not recruiting |
NCT05661799 -
Persistence of Physical Activity in People With Type 2 Diabetes Over Time.
|
N/A | |
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Completed |
NCT02836704 -
Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)
|
Phase 4 | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Completed |
NCT04562714 -
Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy
|
N/A | |
Completed |
NCT02009488 -
Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
Completed |
NCT05896319 -
Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2
|
N/A | |
Recruiting |
NCT05598203 -
Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes
|
N/A | |
Completed |
NCT05046873 -
A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People
|
Phase 1 | |
Completed |
NCT04030091 -
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
|
Phase 4 | |
Terminated |
NCT04090242 -
Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes
|
N/A | |
Completed |
NCT03620357 -
Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)
|
N/A | |
Completed |
NCT03604224 -
A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
|
||
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT03620890 -
Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy
|
Phase 4 | |
Withdrawn |
NCT05473286 -
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Completed |
NCT04531631 -
Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes
|
Phase 2 |